Corcept Therapeutics Incorporated (CORT)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-07-29) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-04-30) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-24) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-04) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-07-31) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-05) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-26) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-10-30) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-07-29) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-01) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-15) · 99.1 | 8-K (2024-01-08) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-01) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Condensed Consolidated Statements of (loss) Income | — |
|
| Consolidated Statements of Income | ||
| Condensed Consolidated Statements of Comprehensive (loss) Income | — |
|
| Consolidated Balance Sheets (P) | — |
|
| Consolidated Statements of Comprehensive Income | ||
| Condensed Consolidated Statements of Comprehensive (loss) Income (P) | — |
|
| Consolidated Statements of Comprehensive Income (P) | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Stockholders' Equity | ||
| Notes | ||
| Available For Sale Marketable Securities and Fair Value Measurements | — |
|
| Available-for-sale Marketable Securities and Fair Value Measurements | — |
|
| Available-for-sale Securities and Fair Value Measurements | — |
|
| Basis of Presentation and Summary of Significant Accounting Policies | ||
| Commitments and Contingencies | ||
| Composition of Certain Balance Sheet Items | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | ||
| Net (loss) Income Per Share | — |
|
| Net Income Per Share | ||
| Pay Vs Performance Disclosure | ||
| Preferred Stock and Stockholders' Equity | — |
|
| Related Party Transactions | — |
|
| Revenue | — |
|
| Significant Agreements | — |
|
| Stock-based Compensation | — |
|
| Stockholders Equity | ||
| Subsequent Events | ||